Market Overview

Johnson & Johnson Completes Divestiture Of Ortho-Clinical Diagnostics To The Carlyle Group For $4B

Share:
Related JNJ
A Look Back At What's Happened To Each Sector Through The First Half Of 2018 (Part 2)
Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study
What Does Breakthrough Therapy Designation Really Mean For My Company? (Seeking Alpha)

Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group for approximately $4 billion, subject to customary adjustments.

Under the terms of the transaction, The Carlyle Group has acquired the Ortho-Clinical Diagnostics business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases. The Ortho-Clinical Diagnostics business generated net sales of approximately $1.9 billion in 2013.

Johnson & Johnson will discuss the financial impact of this divestiture during its scheduled quarterly earnings call on July 15, 2014.

Posted-In: News Health Care Legal Press Releases General

 

Related Articles (JNJ)

View Comments and Join the Discussion!